Cellares, founded in 2019, is a cell therapy manufacturer that strives to develop scalable solutions to accelerate care for people living with a range of diseases. The company is the first Integrated Development and Manufacturing Organization (IDMO), and its Cell Shuttle platform aims to use automation to increase productivity at facilities that manufacture cell therapies for both autologous and allogeneic processes. Cellares is headquartered in San Francisco, California.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/23/2023 | Series C-1 | $30.74MM | $xx.xx | $673.64MM | Koch Disruptive Technologies, Bristol Myers Squibb, DFJ Growth, Willett Advisors, Eclipse, Decheng Capital, 8VC | |
Price per Share
$xx.xx
Shares Outstanding
4,517,033
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Koch Disruptive Technologies, Bristol Myers Squibb, DFJ Growth, Willett Advisors, Eclipse, Decheng Capital, 8VC
|
||||||
08/23/2023 | Series C | $225MM | $xx.xx | $673.64MM | Koch Disruptive Technologies, Bristol Myers Squibb, DFJ Growth, Willett Advisors, Eclipse, Decheng Capital, 8VC | |
Price per Share
$xx.xx
Shares Outstanding
26,450,358
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Koch Disruptive Technologies, Bristol Myers Squibb, DFJ Growth, Willett Advisors, Eclipse, Decheng Capital, 8VC
|
||||||
05/05/2021 | Series B-1 | $2.01MM | $xx.xx | $241.05MM | Decheng Capital, Eclipse Ventures, 8VC, Skyviews Life Science | |
Price per Share
$xx.xx
Shares Outstanding
464,639
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Decheng Capital, Eclipse Ventures, 8VC, Skyviews Life Science
|
||||||
05/05/2021 | Series B | $80MM | $xx.xx | $241.05MM | Decheng Capital, Eclipse Ventures, 8VC, Skyviews Life Science | |
Price per Share
$xx.xx
Shares Outstanding
15,680,430
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Decheng Capital, Eclipse Ventures, 8VC, Skyviews Life Science
|
||||||
10/29/2020 | Series A | $18MM | $xx.xx | $45MM | Eclipse Ventures, 8VC, EcoR1 Capital | |
Price per Share
$xx.xx
Shares Outstanding
12,203,387
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Eclipse Ventures, 8VC, EcoR1 Capital
|